<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00144989</url>
  </required_header>
  <id_info>
    <org_study_id>JCOG0202-MF</org_study_id>
    <secondary_id>C000000095</secondary_id>
    <nct_id>NCT00144989</nct_id>
  </id_info>
  <brief_title>A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC</brief_title>
  <official_title>A Phase III Study Comparing Etoposide and Cisplatin (EP) With Irinotecan and Cisplatin (IP) Following EP Plus Concurrent Accelerated Hyperfractionated Thoracic Irradiation (EP/TRT) for Limited-Stage Small-Cell Lung Cancer : JCOG0202-MF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haruhiko Fukuda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Japan Clinical Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the role of 3 cycles of irinotecan and cisplatin for patients with limited-stage
      small-cell lung cancer who received one course of etoposide and cisplatin plus concurrent
      accelerated hyperfractionated thoracic irradiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Japan Clinical Oncology Group (JCOG) previously conducted a randomized phase III trial
      comparing irinotecan and cisplatin (IP) with EP in patients with extensive-stage SCLC. The
      response rate and overall median survival were significantly better for IP, i.e. 84.4% and
      12.8 months with IP, versus 67.5% and 9.4 months with EP, respectively. The 2-year survival
      rates were 19.5% for IP and 5.2% for EP (7). These encouraging results prompted us to explore
      the use of IP in LSCLC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>during the study conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events of induction chemoradiotherapy</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chemotherapy after chemoradiotherapy</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late radiation morbidity</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serious adverse event</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">281</enrollment>
  <condition>Small-Cell-Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etoposide and cisplatin after chemoradiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan and cisplatin after chemoradiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide and cisplatin after chemoradiotherapy</intervention_name>
    <description>Etoposide and cisplatin after chemoradiotherapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan and cisplatin after chemoradiotherapy</intervention_name>
    <description>Irinotecan and cisplatin after chemoradiotherapy</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. cytologically, histologically proven small-cell lung cancer

          2. limited disease

          3. age 20-70 years old

          4. performance status of 0-1

          5. measurable disease

          6. no prior treatment for small-cell lung cancer

          7. no history of chemotherapy

          8. adequate organ functions

          9. written informed consent

        Exclusion Criteria:

          1. pericardial effusion

          2. active concomitant malignancy

          3. pregnant or lactating women

          4. interstitial pneumonia/active lung fibrosis on chest x-ray, watery diarrhea,
             intestinal obstruction or paralysis, uncontrolled heart disease or a history of
             myocardial infarction within the previous 6 months, uncontrolled diabetes mellitus,
             active infection, psychological disease deemed unacceptable for inclusion to the
             study, long-term steroid treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yutaka Nishiwaki, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Center Hospital East</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya,Chikusa-ku,Kanokoden,1-1</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center,Aichi Hospital</name>
      <address>
        <city>Okazaki,Kake-machi,Kuriyado,18</city>
        <state>Aichi</state>
        <zip>444-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa-shi,Kashiwanoha,6-5-1</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center</name>
      <address>
        <city>Matsuyama,Horinouchi,13</city>
        <state>Ehime</state>
        <zip>790-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Higashi-ku,Maidashi,3-1-1</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gifu Municipal Hospital</name>
      <address>
        <city>Gifu,Kashima-cho,7-1</city>
        <state>Gifu</state>
        <zip>500-8323</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma Prefectural Cancer Center</name>
      <address>
        <city>Ota,Takabayashi-nishi-cho,617-1</city>
        <state>Gunma</state>
        <zip>373-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Nishigunma Hospital</name>
      <address>
        <city>Shibukawa,Kanai,2854</city>
        <state>Gunma</state>
        <zip>377-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization, Dohoku National Hospital</name>
      <address>
        <city>Asahikawa,Hanasaki,7-4048</city>
        <state>Hokkaido</state>
        <zip>070-8644</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Hokkaido Cancer Center</name>
      <address>
        <city>Sapporo,Shiroishi-ku,Kikusui,4-2-3-54</city>
        <state>Hokkaido</state>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Medical Center for Adults</name>
      <address>
        <city>Akashi,Kitaouji-cho,13-70</city>
        <state>Hyogo</state>
        <zip>673-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe City General Hospital</name>
      <address>
        <city>Kobe,Chuo-ku,Minatojimanakamachi,4-6</city>
        <state>Hyogo</state>
        <zip>650-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine</name>
      <address>
        <city>Nishinomiya,Mukogawa-cho,1-1</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ibaraki Kenritsu Chuo Hospital &amp; Cancer Center</name>
      <address>
        <city>Nishi-ibarakigun,Tomobemachi,Koibuchi,6528</city>
        <state>Ibaraki</state>
        <zip>309-1793</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Yokohama,Asahi-ku,Nakao,1-1-2</city>
        <state>Kanagawa</state>
        <zip>241-0815</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Mucipical Citizen's Hospital</name>
      <address>
        <city>Yokohama,Hodogaya-ku,Okazawa-cho,56</city>
        <state>Kanagawa</state>
        <zip>240-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Regional Medical Center Hospital</name>
      <address>
        <city>Kumamoto,Honjo,5-16-10</city>
        <state>Kumamoto</state>
        <zip>860-0811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai,Aoba-ku,Seiryo-machi,1-1</city>
        <state>Miyagi</state>
        <zip>980-0874</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital</name>
      <address>
        <city>Niigata,Kawagishi-cho,2-15-3</city>
        <state>Niigata</state>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama,Shikata-cho,2-5-1</city>
        <state>Okayama</state>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Prefectural Medical Center for Respiratory and Allergic Disease</name>
      <address>
        <city>Habikino,Habikino,3-7-1</city>
        <state>Osaka</state>
        <zip>583-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rinku General Medical Center</name>
      <address>
        <city>Izumisano,rinku-ohrai-kita,2-23</city>
        <state>Osaka</state>
        <zip>598-0048</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Graduate School of Medicine, Osaka City University</name>
      <address>
        <city>Osaka,Abeno-ku,Asahi-machi,1-5-7</city>
        <state>Osaka</state>
        <zip>545-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Medical Center for Cancer and Cardiovascular Diseases</name>
      <address>
        <city>Osaka,Higashinari-ku,Nakamichi,1-3-3</city>
        <state>Osaka</state>
        <zip>537-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City General Hospital</name>
      <address>
        <city>Osaka,Miyakojima-ku,Miyakojimahondori,2-13-22</city>
        <state>Osaka</state>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka General Medical Center</name>
      <address>
        <city>Osaka,Sumiyoshi-ku,Bandai-higashi,3-1-56</city>
        <state>Osaka</state>
        <zip>558-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki University School of Medicine</name>
      <address>
        <city>Osaka-Sayama,Ohno-higashi,377-2</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kinki-Chuo Chest Medical Center</name>
      <address>
        <city>Sakai,Nagasone,1180</city>
        <state>Osaka</state>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Toneyama National Hospital</name>
      <address>
        <city>Toyonaka,Toneyama,5-1-1</city>
        <state>Osaka</state>
        <zip>560-8552</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center</name>
      <address>
        <city>Kita-adachi,Ina,Komuro,818</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sizuoka Cancer Center</name>
      <address>
        <city>Sunto-gun,Nagaizumi-cho,Shimonagakubo,1007</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tochigi Cancer Center</name>
      <address>
        <city>Utsunomiya,Yohnan,4-9-13</city>
        <state>Tochigi</state>
        <zip>320-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku,Tsukiji,5-1-1</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute Hospital</name>
      <address>
        <city>Koto-ku,Ariake,3-10-6</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital</name>
      <address>
        <city>Minato-ku,Toranomon,2-2-2</city>
        <state>Tokyo</state>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Medical Center of Japan</name>
      <address>
        <city>Shinjuku-ku,Toyama,1-21-1</city>
        <state>Tokyo</state>
        <zip>162-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamagata Prefectural Central Hospital</name>
      <address>
        <city>Yamagata,Aoyagi,1800</city>
        <state>Yamagata</state>
        <zip>990-2292</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.jcog.jp/</url>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Japan Clinical Oncology Group</investigator_affiliation>
    <investigator_full_name>Haruhiko Fukuda</investigator_full_name>
    <investigator_title>JCOG Data Center</investigator_title>
  </responsible_party>
  <keyword>Small-cell lung cancer</keyword>
  <keyword>Limited-Stage Small-Cell Lung Cancer</keyword>
  <keyword>Combined modality therapy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>Cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

